ME02725B - Inhibitori proteazoma za lećenje kancera - Google Patents
Inhibitori proteazoma za lećenje kanceraInfo
- Publication number
- ME02725B ME02725B MEP-2017-106A MEP10617A ME02725B ME 02725 B ME02725 B ME 02725B ME P10617 A MEP10617 A ME P10617A ME 02725 B ME02725 B ME 02725B
- Authority
- ME
- Montenegro
- Prior art keywords
- treating cancer
- proteasome inhibitors
- proteasome
- inhibitors
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24771409P | 2009-10-01 | 2009-10-01 | |
| PCT/EP2010/005994 WO2011038924A2 (en) | 2009-10-01 | 2010-10-01 | Treatment of disease with proteasome inhibitors |
| EP10807320.6A EP2519231B1 (en) | 2009-10-01 | 2010-10-01 | Proteasome inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02725B true ME02725B (me) | 2017-10-20 |
Family
ID=43629456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-106A ME02725B (me) | 2009-10-01 | 2010-10-01 | Inhibitori proteazoma za lećenje kancera |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110189204A1 (me) |
| EP (1) | EP2519231B1 (me) |
| JP (1) | JP2013506626A (me) |
| AU (2) | AU2010300259A1 (me) |
| CA (1) | CA2776327A1 (me) |
| CY (1) | CY1118925T1 (me) |
| DK (1) | DK2519231T3 (me) |
| ES (1) | ES2624644T3 (me) |
| HR (1) | HRP20170702T1 (me) |
| HU (1) | HUE032571T2 (me) |
| LT (1) | LT2519231T (me) |
| ME (1) | ME02725B (me) |
| PL (1) | PL2519231T3 (me) |
| PT (1) | PT2519231T (me) |
| RS (1) | RS55931B1 (me) |
| SI (1) | SI2519231T1 (me) |
| WO (1) | WO2011038924A2 (me) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013071142A1 (en) * | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| AU2015340359B2 (en) * | 2014-10-30 | 2019-11-21 | Big Dna Ltd | Combination therapy |
| WO2017070328A1 (en) * | 2015-10-20 | 2017-04-27 | The Cleveland Clinic Foundation | STIMULATION OF 11β-HSD2 EXPRESSION TO IMPROVE HORMONAL THERAPY OF STEROID-DEPENDENT DISEASE |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4499802A (en) * | 1982-09-29 | 1985-02-19 | Container Graphics Corporation | Rotary cutting die with scrap ejection |
| US4537773A (en) * | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| US5081110A (en) * | 1986-03-27 | 1992-01-14 | Sloan-Kettering Institute For Cancer Research | Method of killing sarcoma cells using fludarabine phosphate and ionizing radiation |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| CA2362426A1 (en) * | 1999-02-10 | 2000-08-17 | Takashi Tsuruo | Anticancer drug enhancer |
| CA2435146C (en) | 2001-01-25 | 2011-03-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| BRPI0606455A (pt) | 2005-01-21 | 2008-03-11 | Astex Therapeutics Ltd | compostos farmacêuticos |
| EP1845975A1 (en) | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
| US20060193844A1 (en) * | 2005-02-28 | 2006-08-31 | Proteolix, Inc. | Methods for enzyme inhibition |
| US7998938B2 (en) * | 2005-04-15 | 2011-08-16 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| WO2008086005A1 (en) | 2007-01-09 | 2008-07-17 | University Of South Florida | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| KR101544498B1 (ko) * | 2007-08-24 | 2015-08-17 | 스티칭 허트 네덜란드 칸커 인스티튜트 | 종양성 질환의 치료를 위한 조성물 |
-
2010
- 2010-10-01 AU AU2010300259A patent/AU2010300259A1/en not_active Abandoned
- 2010-10-01 PT PT108073206T patent/PT2519231T/pt unknown
- 2010-10-01 PL PL10807320T patent/PL2519231T3/pl unknown
- 2010-10-01 HU HUE10807320A patent/HUE032571T2/en unknown
- 2010-10-01 LT LTEP10807320.6T patent/LT2519231T/lt unknown
- 2010-10-01 WO PCT/EP2010/005994 patent/WO2011038924A2/en active Application Filing
- 2010-10-01 US US12/896,289 patent/US20110189204A1/en not_active Abandoned
- 2010-10-01 ME MEP-2017-106A patent/ME02725B/me unknown
- 2010-10-01 JP JP2012531285A patent/JP2013506626A/ja active Pending
- 2010-10-01 EP EP10807320.6A patent/EP2519231B1/en not_active Revoked
- 2010-10-01 SI SI201031448A patent/SI2519231T1/sl unknown
- 2010-10-01 ES ES10807320.6T patent/ES2624644T3/es active Active
- 2010-10-01 RS RS20170474A patent/RS55931B1/sr unknown
- 2010-10-01 DK DK10807320.6T patent/DK2519231T3/en active
- 2010-10-01 CA CA2776327A patent/CA2776327A1/en not_active Abandoned
-
2016
- 2016-12-22 AU AU2016277700A patent/AU2016277700A1/en not_active Abandoned
-
2017
- 2017-05-11 HR HRP20170702TT patent/HRP20170702T1/hr unknown
- 2017-06-01 CY CY20171100580T patent/CY1118925T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011038924A3 (en) | 2011-05-26 |
| WO2011038924A9 (en) | 2011-07-14 |
| DK2519231T3 (en) | 2017-06-26 |
| HUE032571T2 (en) | 2017-09-28 |
| EP2519231A2 (en) | 2012-11-07 |
| JP2013506626A (ja) | 2013-02-28 |
| US20110189204A1 (en) | 2011-08-04 |
| EP2519231B1 (en) | 2017-03-15 |
| AU2010300259A1 (en) | 2012-04-26 |
| PT2519231T (pt) | 2017-05-25 |
| ES2624644T3 (es) | 2017-07-17 |
| CA2776327A1 (en) | 2011-04-07 |
| SI2519231T1 (sl) | 2017-07-31 |
| HRP20170702T1 (hr) | 2017-07-14 |
| PL2519231T3 (pl) | 2017-09-29 |
| LT2519231T (lt) | 2017-05-10 |
| RS55931B1 (sr) | 2017-09-29 |
| CY1118925T1 (el) | 2018-01-10 |
| AU2016277700A1 (en) | 2017-02-02 |
| WO2011038924A2 (en) | 2011-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200363A1 (en) | Compounds useful for treating cancer | |
| HUE060305T2 (hu) | FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére | |
| HK1175476A1 (en) | Cancer treatment | |
| IL218987A0 (en) | Methods and compositions for treating cancer | |
| ZA201205004B (en) | Methods for treating pancreatic cancer | |
| EP2461835A4 (en) | COMPOSITIONS WITH JARID1B INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER | |
| EP2424516A4 (en) | PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER | |
| EP2635286A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP2419136A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
| IL196208A0 (en) | Methods for cancer treatment using tak1 inhibitors | |
| IL218230A0 (en) | Method of treating cancer | |
| EP2768512A4 (en) | ENZYME HAMMER FOR CANCER TREATMENT | |
| EP2560648A4 (en) | METHOD OF TREATING PANCREATIC CANCER | |
| RS55931B1 (sr) | Inhibitori proteazoma za lečenje kancera | |
| ZA201201894B (en) | Pharmaceutical combination for treating tumor | |
| PT2509599E (pt) | Processo para o tratamento de cancro pancreático | |
| EP2250290A4 (en) | PTTG1 AS A BIOMARKER FOR CANCER TREATMENT | |
| IL215199A0 (en) | Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer | |
| EP2403963A4 (en) | BIOMARKER AND TREATMENT FOR CANCER | |
| GB0914322D0 (en) | Compounds for treating cancer | |
| GB201019034D0 (en) | Treatment for tumors |